Back to Acceleration Radar
CORTCorcept Therapeutics Incorporated
Health Care · Biotechnology: Pharmaceutical Preparations · Large
$85.86−20.13%
As of 23 Oct 2026Mkt cap $11.9B
Stage 13
AVOID
Fundamentals
32.7/75
Technical
6.0/15
Independent
38.7/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −27.6%
- 3M
- −5.8%
- 6M
- +86.4%
- 1Y
- +16.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 204.4xHist median 55.3x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 96.4x
- FCF yield
- 1.0%
Quality
- ROIC
- —
- Operating margin
- 20.3%
- FCF margin
- 18.6%
- Current ratio
- 2.9x
Growth
- Revenue growth
- +12.8%Latest FY YoY
- Revenue CAGR
- +20.1%
- EPS CAGR
- −2.0%
- FCF CAGR
- −4.1%
Capital
- Share-count trend
- +3.6%3Y annualised
- Net cash
- $114M-0.8x OCF
Annual trend
- CAGR 2021–2025
- +20.1%
- Latest · 2025
- $1B
- YoY
- +12.8%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded